Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Hinchey Calls On FDA To Investigate Agency Knowledge Of Prozac Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Maurice Hinchey (D-N.Y.) requests that FDA conduct an investigation into what the agency did or did not know about Lilly documents regarding a possible link between Prozac (fluoxetine) and increased suicidality and violence

You may also be interested in...



British Medical Journal Apologizes To Lilly For Prozac Article

In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”

British Medical Journal Apologizes To Lilly For Prozac Article

In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”

Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims

Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel